Roche loses appeal to block market entry of rival cancer drug
07-07-2020
Hatch-Waxman amendment: a Hobson’s choice
08-08-2018
Senator proposes Hatch-Waxman change to boost generic development
15-06-2018
berezko / iStockphoto.com
The inter partes review (IPR) process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AIPPI 2018, Eli Lilly, IPR, inter partes review, biosimilar, UCB, Manisha Desai, Mark Stewart
